



幹細胞を用いた
化学物質リスク情報共有化コンソーシアム
Stem Cell-based Chemical Risk Information Sharing Consortium (scChemRISC)


“Challenges and issues of new safety evaluation by next-generation technologies” – Tokyo, Oct 16-17, 2019

Profiling the ToxCast library with a pluripotent human (H9) embryonic stem cell assay



Thomas B. Knudsen, PhD
Developmental Systems Biologist
Center for Computational Toxicology and Exposure
Research Triangle Park NC 27711

knudsen.thomas@epa.gov
[ORCID 0000-0002-5036-596x](https://orcid.org/0000-0002-5036-596x)



DISCLAIMER: The views expressed are those of the presenters and do not reflect Agency policy.

An official website of the United States government.

We've made some changes to EPA.gov. If the information you are looking for is not here, you may be able to find it on the EPA Web Archive or the January 19, 2017 Web Snapshot. Close X

EPA United States Environmental Protection Agency

Environmental Topics Laws & Regulations About EPA Search EPA.gov

Administrator Memo Prioritizing Efforts to Reduce Animal Testing, September 10, 2019

On September 10, 2019, U.S. Environmental Protection Agency Administrator Andrew Wheeler signed a directive that prioritizes efforts to reduce animal testing. [Learn more about EPA efforts to reduce animal testing at EPA.](https://www.epa.gov/research/administrator-memo-prioritizing-efforts-reduce-animal-testing-september-10-2019)

<https://www.epa.gov/research/administrator-memo-prioritizing-efforts-reduce-animal-testing-september-10-2019>

- EPA is evaluating new approach methodologies (NAMs) that can be used to quickly evaluate the human toxicity potential of chemicals with less reliance on animal testing.
- Sept 10 directive by Administrator Wheeler calls for reducing mammalian study requests 30% by 2025 and eliminating them by 2035.

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460
September 10, 2019

THE ADMINISTRATOR

MEMORANDUM

SUBJECT: Directive to Prioritize Efforts to Reduce Animal Testing

FROM: Andrew R. Wheeler, Administrator

TO: Associate Deputy Administrator
General Counsel
Assistant Administrators
Inspector General
Chief Financial Officer
Chief of Staff
Associate Administrators
Regional Administrators


During my March 2019 all-hands address, I reiterated the U.S. Environmental Protection Agency's commitment to move away from animal testing. We are already making significant efforts to reduce, replace and refine our animal testing requirements under both statutory and strategic directives. For example, the *Toxic Substances Control Act*, amended June 22, 2016, by the Frank R. Lautenberg Chemical Safety for the 21st Century Act, requires the EPA to reduce reliance on animal testing. Also, Objective 3.3 of the *FY 2018-2022 U.S. EPA Strategic Plan* outlines a commitment to further reduce the reliance on animal testing within five years. More than 200,000 laboratory animals have been saved in recent years as a result of these collective efforts.

Scientific advancements exist today that allow us to better predict potential hazards for risk assessment purposes without the use of traditional methods that rely on animal testing. These new approach methods (NAMs), include any technologies, methodologies, approaches or combinations thereof that can be used to provide information on chemical hazard and potential human exposure that can avoid or significantly reduce the use of testing on animals. The benefits of NAMs are extensive, not only allowing us to decrease animals used while potentially evaluating more chemicals across a broader range of potential biological effects, but in a shorter timeframe with fewer resources while often achieving equal or greater biological predictivity than current animal models.


Internet Address (URL): <http://www.epa.gov>
Recycled/Recyclable • Printed with Vegetable Oil Based Inks on 100% Postconsumer, Process Chlorine Free Recycled Paper

Shifting toxicology to NAM-based approaches

ToxCast




Tox21



1,000,000's concentration responses!

*Translation is key: how well do these
in vitro profiles predict adverse
developmental outcomes?
(predictive DART)*





October is National Children's Health Month


Problem statement: *predictive DART*

- **Objective:** increase the diversity and relevance of assays in ToxCast that can be used to profile chemicals for potential adverse effects on human embryonic development.
- Chemical exposure to a pregnant woman has the potential to affect her unborn child, leading to adverse birth outcomes and/or risks to early child development.
- Traditional animal-based methods for assessing prenatal developmental toxicity (OECD TG 414) expose pregnant rats and/or rabbits during organogenesis and necropsy at term.
- Under reauthorized TSCA (2016) EPA must accelerate development of scientifically valid test methods to prioritize large numbers of chemicals with less reliance on animal testing.

devTOX^{qP} assay: Stemina Biomarker Discovery, EPA contract EP-D-13-055


Birth Defects Research Part B

Developmental and Reproductive Toxicology


Explore this journal >

Original Article


Establishment and Assessment of a New Human Embryonic Stem Cell-Based Biomarker Assay for Developmental Toxicity Screening

Jessica A. Palmer , Alan M. Smith, Laura A. Egnash, Kevin R. Conard, Paul R. West, Robert E. Burrier, Elizabeth L.R. Donley, Fred R. Kirchner

First published: August 2013 [Full publication history](#)


DOI: 10.1002/bdrb.21078 [View/save citation](#)

Cited by (CrossRef): 18 articles [Check for updates](#) [Citation tools](#)



View issue TOC
Volume 98, Issue 4
August 2013
Pages 343–363

Pluripotent H9 human embryonic stem cell metabolomics assay that “... identified the potential developmental toxicants in the test set with 77% accuracy (57% sensitivity, 100% specificity).”

Palmer et al. 2013




Ornithine release
urea cycle, polyamine &
pyrimidine synthesis.





TI = ORN/CYSS

Cystine utilization
glutathione synthesis,
redox cycling.



ToxCast_STM workflow: *ToxCast chemical library (1065 chemicals in Phase I/II)*


- pluripotent human embryonic stem cells (H9 line) exposed for 3-days
- concentration response on 334 chemicals; single concentration screen on 731 inactives
- (additional testing underway on 307 chemicals)
- data processed through the ToxCast pipeline (tcpl, level 6)
- readout is concentration that induces a critical drop in the biomarker ($\text{ORN}/\text{CYSS} \leq 0.76$)




SOURCE: Zurlinden et al. (submitted)

ToxCast_STM results

Plate-level controls and tcpl samples




Positivity on 181 of 1065 (17%) ToxCast chemicals (Phase I, II)





Metabolic pair: Benomyl and its conversion product (Carbendazim)

Targeted biomarker (TI)






Viable cell number (CV)



Benomyl

TI = 3.53 μM, CV = 3.63 μM
dLEL rat = 62.5 mg/kg/day (< mLEL)
dLEL rabbit = 180 mg/kg/day (mLEL)





Carbendazim




TI = 6.12 μM, CV = no effect
dLEL rat = 20 mg/kg/day (< mLEL)
dLEL rabbit (no ToxRefDB entry)

Stereoisomers: *R*-enantiomer (Fluazifop-P-butyl) is the active herbicide

Targeted biomarker (TI)




Viable cell number (CV)



Fluazifop butyl

TI = not active, CV = no effect
 dLEL rat = 10 mg/kg/day (< mLEL)
 dLEL rabbit = 90 mg/kg/day (mLEL)



Fluazifop-P-butyl

TI = 26 μM, CV = 40.8 μM
 dLEL rat = 5 mg/kg/day (< mLEL)
 dLEL rabbit = 50 mg/kg/day (mLEL)

DevTox Performance Check


- ToxCast has 42 benchmark compounds often used to validate alternative DevTox platforms¹.
- Accuracy = 78.6% (0.65 sens, 1.00 spec) consistent with pharma-trained model.

How does the STM prediction do with ToxRefDB (v1) prenatal developmental toxicity studies?

¹ Genschow et al. 2002; West et al. 2010; Daston et al. 2014; Augustine-Rauch et al. 2016; Wise et al. 2016


CASRN	Chemical	HTC ¹ (μM)	CV ² (μM)	TI ³ (μM)	Preg.class ⁴	STM class ⁵
302-79-4	all-trans-Retinoic acid	10	NA	0.003	X	TP
69-74-9	Cytarabine hydrochloride	1	0.083	0.054	D	TP
59-05-2	Methotrexate	1	0.062	0.059	X	TP
147-24-0	Diphenhydramine hydrochloride	100	3.76	0.588	B	TP
50-35-1	Thalidomide	100	NA	1.27	X	TP
51-21-8	5-Fluorouracil	1	1.45	2.02	D	TP
298-46-4	Carbamazepine	100	NA	2.29	C	TP
55-98-1	Busulfan	100	4.91	2.31	D	TP
13292-46-1	Rifampicin	10	NA	2.46	C	TP
19774-82-4	Amiodarone hydrochloride	10	NA	5.1	D	TP
75330-75-5	Lovastatin	20	NA	5.1	X	TP
3056-17-5	Stavudine	100	NA	32.5	C	TP
2392-39-4	Dexamethasone sodium phosphate	100	21.8	37.7	C	TP
53-86-1	Indomethacin	100	44.1	72.7	D	TP
127-07-1	Hydroxyurea	1000	237	74.9	D	TP
127-01-1	Valproic acid	1000	271	155	D	TP
4376-20-9	MEHP	500	NA	167	D	TP
57-41-0	5,5-Diphenylhydantoin	100	NA	NA	D	FN
51-52-5	6-Propyl-2-thiouracil	100	NA	NA	D	FN
10043-35-3	Boric acid	40.7	NA	NA	NTP	FN
4449-51-8	Cyclopamine	10	NA	NA	D	FN
6055-19-2	Cyclophosphamide monohydrate	20	NA*	NA	D	FN
56-53-1	Diethylstilbestrol	10	NA	NA	X	FN
107-21-1	Ethylene glycol	100000	NA	NA	NTP	FN
57-30-7	Phenobarbital sodium	100	NA*	NA	D	FN
81-81-2	Warfarin	100	NA	NA	X	FN
69-72-7	Salicylic acid	1000	1795	513	C	TN
103-90-2	Acetaminophen	100	NA*	NA	B	TN
79-06-1	Acrylamide	36	NA	NA	NTP	TN
50-78-2	Aspirin	100	NA*	NA	C	TN
80-05-7	Bisphenol A	100	39.4	NA	NTP	TN
94-26-8	Butylparaben	100	NA	NA	GRAS	TN
58-08-2	Caffeine	500	NA	NA	B	TN
464-49-3	D-Camphor	20	NA	NA	C	TN
131-11-3	Dimethyl phthalate	100	NA	NA	NTP	TN
59-30-3	Folic acid	100	NA	NA	A	TN
54-85-3	Isoniazid	8.8	NA*	NA	C	TN
57-55-6	1,2-Propylene glycol	1000000	246664	327552	NTP	TN
68-26-8	Retinol	10	NA	NA	A	TN
81-07-2	Saccharin	100	NA	NA	A	TN
134-03-2	Sodium L-ascorbate	20	NA*	NA	A	TN
599-79-1	Sulfasalazine	100	NA*	NA	B	TN
True Positive Rate (sensitivity)			0.29	0.65		
True Negative Rate (specificity)			0.94	1		
Overall Accuracy			55.00%	78.60%	(MCC = 0.647)	

Binary classification model: fetal endpoints (dLEL) from ToxRefDB



- **Key point:** BAC 78% (0.63 sensitivity, 0.91 specificity, n=127) where evidence for DevTox is strong, but drops as evidence weakens due to ↓ sensitivity.

		Stringency Filter Applied to DevTox Anchor				
Condition ²		Base ^{3,4}	Low ^{3,5}	Medium ^{3,6}	High ^{3,7}	BM-42 ³
in vitro	TP	85	60	35	19	17
	FP	14	37	23	9	0
	FN	217	127	51	11	9
	TN	116	208	176	88	16
	n	432	432	285	127	42
	sensitivity	0.281	0.321	0.407	0.633	0.654
in vivo	specificity	0.892	0.849	0.884	0.907	1.000
	Rand ACC	46.5%	62.0%	74.0%	84.3%	78.6%
	PPV	0.859	0.619	0.603	0.679	1.000
	NPV	0.348	0.621	0.775	0.889	0.640
	BAC	60.3%	62.0%	68.9%	78.4%	82.0%
	MCC	0.190	0.202	0.332	0.554	0.647





Keystone Pathways

- Functional annotations inferred from mining STM response against biochemical (NVS) features.
- What we can and cannot say about the applicability domain with regards to biochemical targets:

Can machine learning to mine the ToxCast portfolio pick up some of the biology that may be missed by the hESC biomarker?

Key Point: potent MIEs may define what the STM response can and cannot predict.

DevTox mined to >800 ToxCast features




- ML with 5-fold cross-validation on train/test split;
- ~200 ToxCast features correlated with DevTox;
- STM was the top-weighted feature;
- 3 other features tied for next-most informative.

Feature	Assay read-out (what the feature measures)
STM_ORN/CYSS_dn	critical effect of the hESC biomarker
ATG_CRE_cis_up	cis-acting reporter activation via cAMP/CREB
ATG_NRF2_ARE_cis_up	NFE2L2 antioxidant response element
ATG_PXR_cis_up	cis-acting reporter activation via PXR/PXRE

- sets up a hierarchical rules-based decision workflow:
 - Rule 1: STM(+) & CREB3(-) predicts TP (86.4%)
 - Rule 2: CREB3/NRF2/PXR (+) overrides STM(+) as TN
 - Rule 3: STM(-) & PXR(+) OR NRF2(+) predicts TN (91.3%)
 - Rule 4: STM(-) & CREB3/NRF2/PXR(-) condition predicts TN (83.3%)

Refined binary classification model: *ToxCast augmentation (+)*



- **Key point:** Augmenting the hESC response with ToxCast data for 3 adaptive pathways (UPR, ARE, XME) improved positive predictive value to BAC up to 88%.

Condition	Low	Low+	Medium	Medium+	High	High+
TP	60	50	35	33	19	19
FP	37	24	23	13	9	3
FN	127	137	51	53	11	11
TN	207	220	175	185	88	94
n	431	431	284	284	127	127
sensitivity	0.321	0.267	0.407	0.618	0.633	0.633
specificity	0.848	0.902	0.884	0.976	0.907	0.969
Rand ACC	61.9%	62.6%	73.9%	89.8%	84.3%	89.0%
PPV	0.619	0.676	0.603	0.875	0.679	0.864
NPV	0.620	0.616	0.774	0.902	0.889	0.895
BAC	61.9%	64.6%	68.9%	88.9%	78.4%	87.9%
MCC	0.201	0.222	0.331	0.679	0.554	0.676

A diagram below the table showing three horizontal bars (blue, green, and light green) with brackets above them. The blue bar spans the first two columns (Low, Low+). The green bar spans the next two columns (Medium, Medium+). The light green bar spans the last two columns (High, High+).


hESC (predicted) vs rat WEC (observed)

5HPP-33: synthetic thalidomide analog


- T.I. predicted 9.5 μM
- AC50 observed 21.2 μM (embryo viability)


TNP-470: synthetic fumagillin analog

- T.I. predicted 0.01 μM
- AC50 observed 0.04 μM (dysmorphogenesis)



RNAseq: exposure-based potential for DevTox at 4h correlated with changes in common for pathways regulating spliceosome-RNA metabolism and proteasome-ubiquitination.






Bring in the embryology to better understand mechanisms and translate NAMs

Anatomical homeostasis in a self-regulating 'Virtual Embryo'

- EA for self-regulation (fitness measure) - simulation executes randomly paired agents (parent cells) that generate daughter cells mutated in their rules.
- You only need to specify the goal of the computation; EA searches rule-space using 'survival of the fittest' (good solutions propagate, poor solutions discarded).



*SOURCE: Andersen, Newman and Otter
(2006) Am. Assoc. Artif. Intel.*

Agent-Based Models (ABMs)

- nature-inspired *agents* (cells) and *rules* (behaviors) are set into motion as a self-organizing virtual system, using an open-source modeling environment (CompuCell3d.org).
- soft-computing uses 'fuzzy logic' to simulate forces or properties governing cell fate and behavior where rules are inexact or knowledge incomplete ([computational intelligence](#)).
- can change course in response to a particular situation or stimulus, such as genetic errors or biomolecular lesions introduced from real world data ([dynamic translation](#)).
- probabilistic rendering of where, when and how a particular condition might lead to an adverse developmental outcome ([cybermorphs](#)).

Translating cellular lesions into quantitative phenotypes

Core Developmental Processes

Patterning (Sets up Future Events)
Timing (Clocks and Oscillators)
Differentiation (Cell Diversification)
Morphogenesis (Tissue Organization)

Cellular Primitives

Growth (Proliferation)
Growth (Volume Increase)
Death (Apoptosis)
Differentiation (Function)
Adhesion (Differential Hypothesis)
Shape (Geometry)
Motility (Cell Migration)
Extra Cellular Matrix (Remodeling)


Morphogenetic Movement

Folding
Epiboly
Convergent Extension
Branching Morphogenesis
Cell Condensation
Cell Sorting
Trans-Differentiation
Cavitation
Involution/Invagination
Tractional Forces

Directed Cell Movement

Contact Guidance (Boundaries)
Haptotaxis (ECM Tracks)
Chemotaxis (Chemical Signals)


- Morphogenesis is fundamentally complex; the hallmark resides in the ability of cells to interact with one another.
- Genetic signals setup spatial information that cells then translate into a coordinated biological response.
- Just as ‘the Cell’ is the basic unit of biology, so too should it be the computational unit (‘Agent’) for modeling the embryo.






Computational Intelligence



<https://www.thescientist.com> May, 2019




Somite development




Differential cell adhesion

- clock genes do not oscillate
- somites form simultaneously






- *FGF8 wavefront restores sequentiality*
- *oscillatory clock improves regularity*







Translating genetic control circuits into phenotypes with C.I.

Control Network





- biological wiring diagram maps cell-cell signaling
- we code the signal-response for individual cell types
- and enable 'steppables' of individual cell behavior in CompuCell3d.org
- executing the simulation triggers signal-response behaviors
- can quantitatively monitor emergent properties





Introducing cellular lesions into the swarm ...

- SI addresses collective behavior of a complex self-organizing system emerging from local interactions.
- Agents work together in closed-loop systems (e.g., flocks, schools, colonies, swarms) → phenotype.
- Subtle details in the simulation can greatly influence the outcome (checkpoints?).





Brain angiogenesis


Tata et al. (2015) *Mechanism Devel*



VEGF-A gradient: NPCs in subventricular zone





- endothelial tip cell
- endothelial stalk cell
- microglial cell



SOURCE: Zurlinden, Kate Saili (2018) – NCCT, unpublished








Executing a simulated dose-response





Critical concentration of Mancozeb on brain angiogenesis:

- predicted from *in silico* model $\sim 0.5 \mu\text{M}$ (Zurlinden, NCCT)
- observed in 3D organotypic culture model of the hNVU $\sim 0.3 \mu\text{M}$ (Daly, UWisc)

Sexual dimorphism: *genital tubercle development*




Androgen virulization: *closure rates @4000 MCS \int androgen supply*



Closure indices (simulated, n=10)



LEFT: androgen insufficiency

RIGHT: delayed virulization




Palatal fusion



Control network



Cybermorphs






Bistable switch



SOURCE: Hutson et al. (2017) Chem Res Toxicol

Smart model ...

Messin' with the switch: *two scenarios for bistable dynamics*




**Narrow
hysteresis:**
*less resilient
but reversible*

**Broad
hysteresis:**
*more resilient
but irreversible*

ToxCast dataset: 39 \uparrow EGF-signaling; some also \downarrow TGF-beta signaling

ChemicalName	EGFR_up (uM AC50)	TGFb1_down (uM AC50)	STM (uM TI)	ToxRefDB (low)
Carbaryl	0.07	1000.00	2.92	POS
Captafol	1.02	3.76	0.35	POS
Fipronil	1.18	1000.00	66.01	POS
Fluazinam	2.39	2.48	10.75	POS
Imidacloprid	4.45	6.95	8.26	POS
Linuron	10.91	1000.00	30.94	POS
Maneb	0.01	1000.00	NEG	POS
Propoxur	1.67	1000.00	NEG	POS
Captan	4.59	7.15	NEG	POS
Bendiocarb	8.75	1000.00	NEG	POS
Raloxifene hydrochloride	12.40	15.94	NEG	POS
Tri-allate	19.19	x	NEG	POS
Triflumizole	32.71	19.88	NEG	POS
Butachlor	32.71	17.85	NEG	POS
Rotenone	0.82	1000.00	0.05	NEG
Zoxamide	14.22	17.37	16.13	NEG
Diuron	16.51	1000.00	68.06	NEG
Forchlorfenuron	0.02	1000.00	NEG	NEG
Azamethiphos	0.89	1000.00	NEG	NEG
Methylene bis(thiocyanate)	1.14	5.93	NEG	NEG
2-(Thiocyanomethylthio)benzothiazole	2.28	6.48	NEG	NEG
Methyl isothiocyanate	4.60	1000.00	NEG	NEG
Bromacil	20.50	1000.00	NEG	NEG
Diphenylamine	32.71	5.95	NEG	NEG
TNP-470	7.78	3.97	0.02	x
PharmaGSID_48511	12.19	11.22	0.02	x
4-Pentylaniline	0.00	x	NEG	x
Monobutyl phthalate	0.01	1000.00	NEG	x
Estrone	0.03	1000.00	NEG	x
SAR102779	0.05	12.95	NEG	x
Niclosamide	0.58	1000.00	NEG	x
CP-457920	3.50	1000.00	NEG	x
Perfluoroundecanoic acid	6.81	4.76	NEG	x
1,2-Benzisothiazolin-3-one	8.22	11.91	NEG	x
SB243213A	10.24	x	NEG	x
Phenolphthalein	16.26	x	NEG	x
FR167356	17.65	1000.00	NEG	x
SB281852	34.72	1000.00	NEG	x
p,p'-DDT	38.17	x	NEG	x


ChemicalName	EGFR_up (uM AC50)	TGFb1_down (uM AC50)	STM (uM TI)	ToxRefDB (low)
Fluazinam	2.39	2.48	10.75	POS
Captan	4.59	7.15	NEG	POS
Diuron	16.51	1000.00	68.06	NEG
FR167356	17.65	1000.00	NEG	x



- BSK_hDFCGF_EGFR_up - Captan (133-06-2) -
- BSK_BE3C_TGFb1_down - Captan (133-06-2) -
- BSK_hDFCGF_EGFR_up - Diuron (330-54-1) -
- BSK_BE3C_TGFb1_down - Diuron (330-54-1) -
- BSK_hDFCGF_EGFR_up - Triflumizole (68694-11-1) -
- BSK_BE3C_TGFb1_down - Triflumizole (68694-11-1) -
- BSK_hDFCGF_EGFR_up - FR167356 (174185-16-1) -
- BSK_BE3C_TGFb1_down - FR167356 (174185-16-1) -

***In silico* dose-response: translating \uparrow EGFR conc. profile into a critical dose**


Fluazinam




Captan



Diuron




FR167356




Pathogenesis: *simulating the perfusion alterations*


pre-critical dose




post-critical dose



Predictive model: *modeling the critical phenomenon*




INPUT: switch dynamics



tipping point predicted by
computational dynamics
(hysteresis switch)


Captan in ToxCast



OUTPUT: tipping point
mapped to concentration
response (4 μ M)

Captan in ToxRefDB
NOAEL = 10 mg/kg/day
LOAEL = 30 mg/kg/day


human HTTK model
2.39 mg/kg/day would
achieve a steady state of
4 μ M in fetal plasma



VTLS

- access to models & simulations
- VT-KB (knowledgebase)
- Literature mining
- tied to ToxCastDB
- high-performance computing

vtls.epa.gov/



Summary and Conclusions

1. Several new approach methods (NAMs) are available for high-throughput screening chemical inventories for DevTox potential.

- STM assay in ToxCast gives an exposure-based readout of a chemical's DevTox hazard potential with 84% balanced accuracy.
- Assay sensitivity predicted high for kinase signaling converging on FoxO signaling but weak for estrogenic (ESR1) and G(q) signaling.

2. Cell ABMs recapitulate morphogenesis cell-by-cell and interaction-by-interaction as an embryonic system advances in time.

- Computer models simulate key events in AOPs to render mechanistic predictions and critical phenomena for DevTox.

*Computer modeling
is 3R's compliant!*



<https://www.pinterest.com/courtney1882/disney-ratatouille/>

Special Thanks



<https://doi.org/10.1021/acs.chemtox.7b00111>

Barbara Abbott – NHEERL (retired)
Nancy Baker – Leidos /CCTE
Dave Belair – NHEERL (now CellGene)
John Cowden – CCTE/CSS
George Daston – Procter & Gamble Co.
Rob Ellis-Hutchings – Dow Chemicals
Florent Ginhoux – A*STAR Singapore
James Glazer – Indiana University
Sid Hunter – NHEERL
Shane Hutson – Vanderbilt University
Richard Judson – CCTE
William Murphy – University of Wisconsin
Aldert Piersma – RIVM, The Netherlands
Kate Saili – NCCT (now OAQ)
Richard Spencer – Leidos / EMVL
Todd Zurlinden – CCTE



EPA contract EP-D-13-055

Michael Colwell – Stemina
Jessica Palmer - Stemina



Tox21 Cross-Partner Project #6

Nicole Kleinstreuer – NICEATM / NTP / NIEHS
Annie Lumen – NCTR / FDA
Menghang Xia – NCATS / NIH